Please try another search
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely...
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1218 | 1085 | 1240 | 1105 | 1687 | 2881 |
Fund Return | 21.78% | 8.5% | 24.04% | 3.4% | 11.02% | 11.16% |
Place in category | 672 | 427 | 609 | 662 | 468 | 170 |
% in Category | 91 | 53 | 86 | 99 | 72 | 43 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Manulife S2 Ideal US Div incm 100PL | 637.69M | 21.17 | 2.91 | 10.88 | ||
Manulife S2 Idl US Div incm Fd 75PL | 637.69M | 21.69 | 3.34 | 11.23 | ||
Manulife S2 Ideal US Div incm Fd 75 | 637.69M | 21.10 | 2.80 | 10.64 | ||
Manulife S2 Idl US Div incm Fd 100 | 637.69M | 20.51 | 2.30 | 10.23 | ||
Manulife Ideal US Div incm Fd RST | 637.69M | 21.51 | 3.15 | 10.93 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
PH N US Multi Style All Cap Eq D | 9.99B | 34.85 | 14.50 | 13.76 | ||
PH N US Multi Style All Cap Eq F | 9.99B | 35.14 | 14.77 | 14.04 | ||
TD U.S. Blue Chip Equity Fund I CAD | 6.3B | 24.25 | 4.59 | 13.59 | ||
TD U.S. Blue Chip Equity Fund D CAD | 6.3B | 25.43 | 5.60 | - | ||
RBC Priv US Lg Cap Cr Eq Sr F CAD | 6.01B | 34.43 | 14.79 | 14.37 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Manulife US Dividend Income Adv | - | 100.12 | - | - |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | Neutral | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review